01—Abstract
Summary
Summary of the 8-K filed April 9, 2026. Cited figures are marked; the original filing is the authoritative source.
On April 9, 2026, CoreWeave (CRWV) announced two concurrent private offerings under Rule 144A and Regulation S: $1,250 milliona of senior unsecured notes due 2031 and $3,000 million of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional $450 million of the convertible notes.
Both are guaranteed by certain wholly-owned subsidiaries. The company's stated uses are general corporate purposes, including repayment of existing debt, plus fees and expenses. For the convertible notes, a portion of proceeds will fund capped call transactions that are intended to reduce dilution from conversions.
The deck's sources and uses show roughly $4.25 billionb of total sources and uses, which is intended to support continued capital expenditures for AI infrastructure. Pricing, coupon, and conversion terms have not yet been set. They will be determined at pricing, so investors should treat the economics as provisional.
The filing is a financing event, not a change in operating results. Its importance lies in the leverage picture. The supplemental deck shows total debt of about $21.6 billionc at 12/31/2025 (7.0x FY25 Adjusted EBITDA of $3.1 billion).
On an as-adjusted basis for these notes, the deck shows about $34.4 billiond of total debt, or 3.3x LTM Run-Rate Adjusted EBITDA of $16.1 billion. That run-rate figure is a non-GAAP measure that adds $13.0 billion of projected pre-tax profits from new contracts, so it is a forward-looking estimate and not a reported result. Investors should weigh the company's $60.7 billion in remaining performance obligations and contract backlog against its high-cost debt stack, which includes existing 9.25% notes due 2030 and 9.00% notes due 2031 and secured delayed-draw term loans.
The convertible tranche gives the company flexibility. CoreWeave can settle conversions in cash, shares of Class A common stock, or a combination of both, at its election. The capped calls are designed to limit dilution up to a cap price, though the exact cap will be set at pricing.
The 8-K also notes that option counterparty hedging activity could affect CRWV's share price and the notes' trading around pricing and conversion periods. Investors should review the preliminary offering memorandum, the final pricing terms, and the expected use of proceeds in the 2025 10-K before drawing conclusions about dilution or credit quality.
02—Key points
Key Highlights
- $1,250 million senior unsecured notes due 2031 offered in a private 144A/Reg S deal, guaranteed by certain wholly-owned subsidiaries; proceeds for general corporate purposes, including debt repayment.
- $3,000 million convertible senior notes due 2032 offered privately, with a 13-day option for initial purchasers to buy up to an additional $450 million; coupon and conversion rate to be set at pricing.
- Conversions can be settled in cash, Class A shares, or a combination, at CoreWeave's election, giving the company flexibility on dilution.
- Capped call transactions are planned to offset dilution and/or cash payments above principal on conversion, subject to a cap; a portion of convertible proceeds funds their cost.
- Deck sources and uses total about $4.25 billion, with the senior notes and convertible notes each supporting general corporate purposes and capped call costs.
- Pro forma leverage rises materially: deck shows total debt of about $21.6 billion (7.0x FY25 Adjusted EBITDA) today versus about $34.4 billion as adjusted (3.3x LTM Run-Rate Adjusted EBITDA of $16.1 billion, a non-GAAP, forward-looking measure).
- Remaining performance obligations of $60.7 billion as of 12/31/2025 provide a contract backlog reference, though the deck notes backlog is not equivalent to recognized revenue.
03—Questions
Frequently Asked Questions
How much is CoreWeave raising, and what kind of debt is it?
CoreWeave announced intent to sell $1,250 million of senior unsecured notes due 2031 and $3,000 million of convertible senior notes due 2032. The convertible notes include an option for up to an additional $450 million. Both are privately offered to qualified institutional buyers and non-U.S. persons, and both are guaranteed by certain wholly-owned subsidiaries. Final size and pricing depend on market conditions.
What will the money be used for?
The company says the proceeds are for general corporate purposes, including repayment of outstanding indebtedness and payment of offering fees and expenses. A portion of the convertible note proceeds will fund capped call transactions. The deck's sources and uses table indicates about $4.25 billion of total uses, and the company's deck says the proceeds will be used for general corporate purposes, including to fund capital expenditures.
Could the convertible notes dilute existing shareholders?
Potentially, but the company has planned mitigation. Conversions can be settled in cash, shares, or both, at CoreWeave's election. The capped calls are expected to reduce dilution upon conversion and/or offset cash payments above principal, up to a cap price that will be set at pricing. The filing also warns that hedging by option counterparties could affect CRWV's share price around pricing and during conversion periods.
How does this affect CoreWeave's leverage?
Leverage rises meaningfully on a pro forma basis. The supplemental deck shows total debt of about $21.6 billion at 12/31/2025, or 7.0x FY25 Adjusted EBITDA of $3.1 billion. As adjusted for these notes, total debt is about $34.4 billion, or 3.3x LTM Run-Rate Adjusted EBITDA of $16.1 billion. The run-rate figure includes $13.0 billion of projected profits from new contracts, so it is a forward-looking non-GAAP estimate and not reported earnings. Using reported FY25 Adjusted EBITDA, the multiple is much higher.
What terms are still unknown, and what should investors check?
The interest rate on the senior notes and convertible notes, the convertible initial conversion rate, the capped call cap price, and the final sizes are not yet set. These will be determined at pricing. Investors should review the preliminary offering memorandum and the supplemental information in Exhibit 99.3, along with the 2025 Form 10-K, for risk factors, covenant details, and full non-GAAP reconciliations before making investment decisions.
04—Continue